Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.44 |
| ▸ | GSK3A | P49840 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24867082 | 0.92 | GSK3B (0.44) | GSK3BGSK3AMAPK1P2RX7ROCK2 | |
| SCHEMBL25219004 | 0.90 | MAPK1 (0.43) | GSK3BGSK3AMAPK1ROCK2ROCK1 | |
| SCHEMBL25212369 | 0.90 | GSK3B (0.43) | GSK3BGSK3AMAPK1ROCK2ROCK1 | |
| SCHEMBL25208819 | 0.87 | GSK3B (0.40) | GSK3BGSK3AMAPK1P2RX7ROCK2 | |
| SCHEMBL25262173 | 0.86 | GSK3B (0.40) | GSK3BGSK3AMAPK1P2RX7ROCK2 | |
| SCHEMBL24867506 | 0.85 | MAPK14 (0.50) | GSK3BGSK3AMAPK1P2RX7ROCK1 | |
| SCHEMBL24867045 | 0.84 | NTRK1 (0.44) | GSK3BGSK3AMAPK1ROCK2ROCK1 | |
| SCHEMBL25258681 | 0.83 | GSK3B (0.43) | GSK3BGSK3AMAPK1ROCK2ROCK1 | |
| SCHEMBL25218406 | 0.83 | MAPK1 (0.44) | GSK3BGSK3AMAPK1P2RX7ROCK2 | |
| SCHEMBL24867406 | 0.82 | GSK3B (0.44) | GSK3BGSK3AMAPK1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | claimed |
| EP-4192828-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2023-06-14 | — | — | EP | claimed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-4192828-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | GSK3B 2068/4885GSK3A 2067/4885MAPK1 1098/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | GSK3B 2068/4885GSK3A 2067/4885MAPK1 1098/4885 |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | GSK3B 2068/4885GSK3A 2067/4885MAPK1 1098/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | GSK3B 2068/4885GSK3A 2067/4885MAPK1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.